HCPConnect
Clinical Registry
Specialty-focused research, clinical updates, and peer-reviewed trials for modern professionals.
FDA approves bimekizumab for moderate to severe plaque psoriasis: 75% PASI reduction in BE VIVID trial.
Bimekizumab (Bimzelx) approved for moderate to severe plaque psoriasis: 75% skin clearance in BE VIVID trial.
IL-17 and IL-23 biologics for plaque psoriasis: Key comparisons and emerging oral options in 2025.
End of Feed
